SCHEMBL2451254

SCHEMBL2451254

Cc1nc(Cl)c(-c2c(F)cc(F)cc2F)n1-c1ccc(Cl)nc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.35
KCNH2 Q12809 1/20 0.35
POLB P06746 1/20 0.35
PIK3CA P42336 2/20 0.34
STIM1 Q13586 1/20 0.32
ORAI1 Q96D31 1/20 0.32
MTOR P42345 1/20 0.32
CYP11B2 P19099 1/20 0.32
OXTR P30559 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
GLA P06280 1/20 0.31
IDO1 P14902 1/20 0.31
TDO2 P48775 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2451435 0.90 PIK3CA (0.34) GRM5KCNH2PIK3CASTIM1ORAI1
SCHEMBL2451262 0.88 PIK3CA (0.35) GRM5POLBPIK3CASTIM1ORAI1
SCHEMBL2453877 0.87 POLB (0.36) POLBCYP11B2CHRNB4CHRNA3IDO1
SCHEMBL2452981 0.85 OXTR (0.46) OXTR
SCHEMBL1074623 0.84 PIK3CA (0.41) KCNH2POLBPIK3CA
SCHEMBL1074256 0.82 GRM1 (0.43) KCNH2CYP11B2IDO1TDO2
SCHEMBL2452818 0.81 PIK3CA (0.41) PIK3CAMTORCYP11B2GLA
SCHEMBL2450998 0.79 PTGS2 (0.40) POLBOXTRCHRNB4CHRNA3
SCHEMBL1074563 0.79 NOTUM (0.37) GLA
SCHEMBL2448152 0.78 PIK3CA (0.35) GRM5PIK3CASTIM1ORAI1OXTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311649-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2011-12-22 US claimed
EP-2201001-B1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-09-14 EP claimed
EP-2201001-A1 NOVEL IMIDAZOLE DERIVATIVES Syngenta Participations AG (CH) 2010-06-30 EP claimed
WO-2009053101-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2009-04-30 WO claimed
EP-2053044-A1 Novel imidazole derivatives Syngenta Participations AG (CH) 2009-04-29 EP claimed
EP-2053046-A1 Novel imidazole derivatives Syngeta Participations AG (CH) 2009-04-29 EP claimed
WO-2018048969-A1 MULTI-TARGETED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-03-15 WO disclosed
EP-2654433-B1 SANDPAPER MUTANTS OF BACILLUS AND METHODS OF THEIR USE TO ENHANCE PLANT GROWTH, PROMOTE PLANT HEALTH AND CONTROL DISEASES AND PESTS BAYER CROPSCIENCE LP (US) 2017-08-30 EP disclosed
US-20160095321-A1 SANDPAPER MUTANTS OF BACILLUS AND METHODS OF THEIR USE TO ENHANCE PLANT GROWTH, PROMOTE PLANT HEALTH AND CONTROL DISEASES AND PESTS AGRAQUEST, INC. 2016-04-07 US disclosed
US-9185915-B2 Sandpaper mutants of bacillus and methods of their use to enhance plant growth, promote plant health and control diseases and pests BAYER CROPSCIENCE LP (US) 2015-11-17 US disclosed
EP-2654433-A1 SANDPAPER MUTANTS OF BACILLUS AND METHODS OF THEIR USE TO ENHANCE PLANT GROWTH, PROMOTE PLANT HEALTH AND CONTROL DISEASES AND PESTS Bayer Cropscience LP (US) 2013-10-30 EP disclosed
US-20120231951-A1 SANDPAPER MUTANTS OF BACILLUS AND METHODS OF THEIR USE TO ENHANCE PLANT GROWTH, PROMOTE PLANT HEALTH AND CONTROL DISEASES AND PESTS BAYER CROPSCIENCE LP 2012-09-13 US disclosed
WO-2012087980-A1 SANDPAPER MUTANTS OF BACILLUS AND METHODS OF THEIR USE TO ENHANCE PLANT GROWTH, PROMOTE PLANT HEALTH AND CONTROL DISEASES AND PESTS AGRAQUEST, INC. (US) 2012-06-28 WO disclosed
US-20110311649-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2011-12-22 US disclosed
EP-2201001-B1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-09-14 EP disclosed
EP-2201001-A1 NOVEL IMIDAZOLE DERIVATIVES Syngenta Participations AG (CH) 2010-06-30 EP disclosed
WO-2009053101-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2009-04-30 WO disclosed
EP-2053044-A1 Novel imidazole derivatives Syngenta Participations AG (CH) 2009-04-29 EP disclosed
EP-2053046-A1 Novel imidazole derivatives Syngeta Participations AG (CH) 2009-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311649-A1 NOVEL IMIDAZOLE DERIVATIVES CBR3, C3AR1, C1R GRM5 3305/4885KCNH2 72/4885POLB 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.